Australian biotech company loses SIAC claim
An Australian biotechnology company has lost a US$300 million SIAC claim over the development of a medicine designed to treat skin and bloodstream infections.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.